Haemophilia A News and Research

RSS

Hemophilia A is an X-linked, recessive, bleeding disorder caused by a deficiency in the activity of coagulation factor VIII. Affected individuals develop a variable phenotype of hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds. The disorder is caused by heterogeneous mutations in the factor VIII gene which maps to Xq28.

Research sheds light on origins of "junk" DNA

In experiments with transgenic mice, University of Pennsylvania School of Medicine researchers discovered the remaining steps in the complicated process of how the largest class of jumping genes replicates and inserts themselves within the human genome.

7 Feb 2006

First potential treatment for intracerebral hemorrhage

The first potential treatment for strokes that result from bleeding in the brain is under study at the Medical College of Georgia.

18 Jan 2006

Polyphosphate speeds blood clotting and helps clots last longer

A serendipitous comparison prompted by an old scientific image and involving an ancient but understudied molecule may lead to a new treatment strategy for injuries or illnesses in which blood clotting is paramount to survival.

9 Jan 2006

New gene therapy maybe useful for treating muscular dystrophy

A new gene therapy technique that has shown promise in skin disease and hemophilia might one day be useful for treating muscular dystrophy, according to a new study by researchers at Stanford University School of Medicine.

29 Dec 2005

LEDGF protein controls the location of HIV integration in human cells

A human DNA-associated protein called LEDGF is the first such molecule found to control the location of HIV integration in human cells, according to researchers at the University of Pennsylvania School of Medicine.

5 Dec 2005

Technique for inserting genes into specific sites on the genome in liver cells

The genes are inserted into non-coding regions of the genome so there is no danger of interfering with the functioning of other genes. Once inserted, the gene remains a permanent part of the cell's genome.

10 Oct 2005

Gene therapy advance shows potential for developing improved treatment for hemophilia

A virus that typically infects insects could help with the development of gene therapy treatment for Hemophilia A, a condition in which even a bump on the knee can cause serious internal bleeding in people.

22 Aug 2005

Ground-breaking discoveries that provide hope of an alternative treatment option for haemophilia sufferers

Haemophilia is a hereditary blood disease, primarily affecting males, where the blood fails to clot causing potentially life-threatening 'bleeds'. About one in 6000 Australian males is born with haemophilia in severe, moderate or mild form. People with haemophilia rely on intravenous infusion of recombinant Factor VIII clotting protein.

11 Aug 2005

Gene therapy used to successfully treat haemophilia in dogs

Progress in gene therapy to treat haemophilia has been impressive in the past few years. Gene therapy has been used to successfully treat haemophilia in dogs.

9 Aug 2005

Researchers have doubled the potency of a protein that drives blood to clot

...according to research to be published in the July 26 edition of Biochemistry. The study results may have profound implications for the treatment of hemophilia, the inherited blood disorder that causes easy or excessive bleeding in 30,000 Americans.

20 Jul 2005

Experimental drug therapy could open new window for treatment of deadly stroke

A new type of drug therapy that is currently being tested in Canada could significantly reduce the death rate caused by the deadliest form of stroke. According to the Canadian Heart and Stroke Foundation, new developments in stroke research make it more important than ever that Canadians recognize and react to the warning signs of stroke.

9 Jun 2005

Over 3,000 lives lost because of blood bungle by Canadian Red Cross

The Canadian Red Cross has pleaded guilty to distributing contaminated blood supplies. Since getting the tainted blood in the 1980s thousands of Canadians with HIV and hepatitis C were infected and more than 3,000 people have died.

31 May 2005

Premature use of stem cell therapy could put patients at risk

The premature use of stem cell therapy could put many patients at risk of viral or prion diseases unless appropriate safety systems are in place, warn experts in this week’s BMJ.

19 May 2005

Mutations in the HFE gene directly associated with chronic joint disease

Mutations in the HFE gene, which is involved in iron regulation, seem to be directly associated with chronic joint disease (or haemophilic arthropathy) among haemophilic patients, claim a team of Portuguese scientists in the April issue of the journal Blood.

4 Apr 2005

Vaccine prevents deadly pneumonia in African children

Global health leaders today presented new research showing that vaccinating infants against Streptococcus pneumoniae -- a bacterium that causes deadly pneumonia, meningitis and sepsis -- could substantially reduce death and serious illness among children in the developing world. If used widely, a pneumococcal conjugate vaccine could prevent hundreds of thousands of child deaths each year.

28 Mar 2005

Discovery may have implications for the treatment of hemophilia A and B

University of North Carolina at Chapel Hill researchers have made a discovery that may have implications for the treatment of liver-based genetic defects such as hemophilia A and B in humans.

15 Feb 2005

Researchers grow mouth lining into pieces of bio-bandage

University of Michigan researchers are testing a new procedure in which they can take a tiny piece of a person's mouth lining, grow it into a dollar-bill sized piece of tissue and graft that expanded piece into the donor's mouth to heal a wound.

5 Oct 2004

Steps to minimise the risk of onward transmission of vCJD

Selected groups of patients are this week being notified about the results of a risk assessment exercise for blood plasma products.

22 Sep 2004

Wyeth gets approval for needle-less syringe for the treatment of hemophilia

Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.

14 Sep 2004

John Reid has announced further developments concerning variant Creutzfeldt-Jakob disease

He told MPs in a written ministerial statement that an exercise has begun to notify some recipients of blood products about the results of a risk assessment exercise carried out by the Health Protection Agency.

10 Sep 2004